Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 53

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Psychedelic Research: The Current Landscape and Future Directions

Understanding Bad Trips: The Power and Potential of Adverse Psychedelic Experiences

Pα+ Psychedelic Bulletin #168:

Ecopsychology, Plant Dietas, and Plant Consciousness: Building a Relationship with Nature

Women’s Health and Psychedelics – New Insights

Regenerative Business in Psychedelics: A Sustainable Path Forward

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated...

Difficult Conversations, the Need for Culturally Competent Care, and Why Representation...

Load more

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©